INSURE : a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice
Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 20(2024), 14 vom: 03. Apr., Seite 935-950 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leleu, Xavier [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2023-0604 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366878638 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366878638 | ||
| 003 | DE-627 | ||
| 005 | 20240405233354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0604 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366878638 | ||
| 035 | |a (NLM)38197267 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leleu, Xavier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INSURE |b a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IRd | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a ixazomib | |
| 650 | 4 | |a ixazomib-lenalidomide-dexamethasone | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a pooled analysis | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a proteasome inhibitor | |
| 650 | 4 | |a relapsed/refractory | |
| 650 | 4 | |a routine clinical practice | |
| 650 | 4 | |a time-to-next treatment | |
| 650 | 7 | |a Boron Compounds |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Glycine |2 NLM | |
| 650 | 7 | |a TE7660XO1C |2 NLM | |
| 650 | 7 | |a ixazomib |2 NLM | |
| 650 | 7 | |a 71050168A2 |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Lee, Hans C |e verfasserin |4 aut | |
| 700 | 1 | |a Zonder, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Macro, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Ramasamy, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Hulin, Cyrille |e verfasserin |4 aut | |
| 700 | 1 | |a Silar, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Kuhn, Matyas |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Kaili |e verfasserin |4 aut | |
| 700 | 1 | |a Bent-Ennakhil, Nawal |e verfasserin |4 aut | |
| 700 | 1 | |a Cherepanov, Dasha |e verfasserin |4 aut | |
| 700 | 1 | |a Stull, Dawn Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Terpos, Evangelos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 20(2024), 14 vom: 03. Apr., Seite 935-950 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:14 |g day:03 |g month:04 |g pages:935-950 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-0604 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 14 |b 03 |c 04 |h 935-950 | ||